Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Depreciation & Amortization - Total (2019 - 2025)

Sunshine Biopharma's Depreciation & Amortization - Total history spans 7 years, with the latest figure at -$56801.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization - Total fell 389.79% year-over-year to -$56801.0; the TTM value through Dec 2025 reached $176346.0, up 20.36%, while the annual FY2025 figure was $176346.0, 20.36% up from the prior year.
  • Depreciation & Amortization - Total reached -$56801.0 in Q4 2025 per SBFM's latest filing, down from $95821.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization - Total ranged from a high of $95821.0 in Q3 2025 to a low of -$56801.0 in Q4 2025.
  • Average Depreciation & Amortization - Total over 5 years is $22749.3, with a median of $3904.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization - Total: soared 4616.1% in 2023, then tumbled 397.05% in 2024.
  • A 5-year view of Depreciation & Amortization - Total shows it stood at $3184.0 in 2021, then skyrocketed by 353.99% to $14455.0 in 2022, then plummeted by 72.99% to $3904.0 in 2023, then crashed by 397.05% to -$11597.0 in 2024, then plummeted by 389.79% to -$56801.0 in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Depreciation & Amortization - Total are -$56801.0 (Q4 2025), $95821.0 (Q3 2025), and $72533.0 (Q2 2025).